ESR1 and cancer: Triple negative breast cancer (TNBC) encompasses a heterogeneous group of cancers, the treatment of which remains a challenge due to the absence of targetable molecules such as estrogen receptor (ER), progesterone receptor (PR), or epidermal growth factor receptor 2 (HER2).